This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-29. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
=== Environmental impacts === Because of the large amount of production of microwave popcorn bags, they have also become a significant contaminant source (PFCs) to the environment. Due to the disposal of coated paper and manufacturing activities, PFOA has also been detected in wastewater and biosolids. Soil near disposal sites are contaminated by PFOA as well.
On January 1, 1899, after the United States defeated Spain at the end of the Spanish–American War and claimed Cuba as the Military Government of Cuba, Spaniards and the Spanish military left the islands of Cuba returning to mainland Spain, and any major influence of the Grand Lodge of Spain was taken with them. Both of the American Military Governors of Cuba, John R. Brooke and Leonard Wood, were high-ranking Freemasons, as was the President of the United States, William McKinley. On the same day that the Spanish left, on January 1, individual Lodges across Cuba began meeting again regularly. Padilla Lodge was able to purchase an old industrial warehouse in Havana. A mass immigration of US citizens to Cuba brought with it much closer coordination with the mainland American Lodges, and many of the highest-ranking US military government officials took a stance of cooperation with the Lodges in Cuba in order to completely restructure the Cuban Freemasonic system and purge it of Spanish aristocratic influence. These high-ranking officials included Admiral Schley, General Shafter, General Scott, Colonel Theodore Roosevelt and General George M. Moulton.
=== Clinical laboratory === On 3 October 2013, a special ceremony was held at the Sindh Institute of Urology and Transplantation (SIUT) Chablani Medical Center to dedicate its clinical laboratory in memory of Tanveer Abbasi a renowned writer, poet and intellectual of Sindh.
== Therapeutic application == Recombinant BNP, nesiritide, has been suggested as a treatment for decompensated heart failure. However, a clinical trial failed to show a benefit of nesiritide in patients with acute decompensated heart failure. Blockade of neprilysin, a protease known to degrade members of the natriuretic peptide family, has also been suggested as a possible treatment for heart failure. Dual administration of neprilysin inhibitors and angiotensin receptor blockers has been shown to be advantageous to ACE inhibitors, the current first-line therapy, in multiple settings.
Sources: en.wikipedia.org
Peukert argued for an integrated view of Nazi Germany with the social policies to encourage "healthy Aryan" families to have more children, the "social racism" that saw the bodies of "healthy Aryan" women as belonging to the volksgemeinschaft, the effort to sterilize "anti-social families" and the extermination of Jews and Romany as part and parcel of the same project. Likewise, Peukert argued that Nazi Germany was not some freakish "aberration" from the norms of Western civilization, as he noted that the ideas about eugenics and racial superiority that the National Socialists drew upon were widely embraced throughout the Western world. In the same way, Peukert noted in Inside Nazi Germany as part of his argument against the "freakish aberration" view of the Nazi era that homosexual sex had been made illegal in Germany with Paragraph 175 in 1871 and all the Nazis did with the 1935 version of Paragraph 175 was to make it tougher, as the 1935 version of Paragraph 175 made being homosexual in and of itself a criminal offense, whereas the 1871 version of Paragraph 175 had only made homosexual sex a criminal offense. Peukert also noted against the "freakish aberration" view of Nazi Germany that the 1935 version of Paragraph 175 stayed on the statute books in West Germany until 1969 as it was considered to be a "healthy law", leading to German homosexuals who survived the concentration camps continuing to be convicted all through the 1950s and 1960s under exactly the same law that sent them to the concentration camps under the Third Reich.
It is home to the headquarters of three Fortune Global 500 companies, the highest in the region. The nation's best known global companies include Singapore Airlines, Changi Airport, and the Port of Singapore, all of which are among the most-awarded in their respective fields. Singapore Airlines was ranked as Asia's most-admired company, and the world's 19th most-admired company in 2015 by Fortune's annual "50 most admired companies in the world" industry surveys. Other awards it has received include the US-based Travel + Leisure's Best International Airline award, which it has won for 20 consecutive years. Changi Airport connects over 100 airlines to more than 300 cities. The strategic international air hub has more than 480 World's Best Airport awards as of 2015, and is known as the most-awarded airport in the world. Over ten free-trade agreements have been signed with other countries and regions. Singapore is the second-largest foreign investor in India. It is the 14th largest exporter and the 15th largest importer in the world.
The exact frequency of clubbing in the population is not known. A 2008 study found clubbing in 1%, or 15 patients, of 1511 patients admitted to a department of internal medicine in Belgium. Of these, 40%, or 6 patients, had significant underlying disease of various causes, while 60%, or nine patients, had no medical problems after further investigation and remained well over the subsequent year.
The jararaca (Bothrops jararaca) is a species that is often abundant within its range, where it is an important cause of snakebite. It is the best-known venomous snake in the wealthy and heavily populated areas of southeastern Brazil, where it was responsible for 52% (3,446 cases) of snakebites between 1902 and 1945, with a 0.7% mortality rate (25 deaths). The average venom yield is 25–26 milligrams (0.39–0.40 gr) with a maximum of 300 milligrams (4.6 gr) of dried venom. The venom is slightly more toxic than that of the terciopelo or fer-de-lance (B. asper). In mice, the median lethal dose (LD50) is 1.2–1.3 mg/kg IV, 1.4 mg/kg IP and 3.0 mg/kg SC. The lethal dose for a 60 kg adult human is 70 mg.
Tyne and Wear contains green belt interspersed throughout the county, mainly on the fringes of the Tyneside/Wearside conurbation. There is also an inter-urban line of belt helping to keep the districts of South Tyneside, Gateshead, and Sunderland separated. It was first drawn up from the 1950s. All the county's districts contain some portion of belt.
Sources: en.wikipedia.org
== Structure and bonds == Conjugated proteins always have a prosthetic group that is highly associated with the polypeptide chain. Association can occur either through covalent bonding or strong noncovalent interactions like hydrogen bonding, ionic bonding, or coordination bonding. Depending on whether the prosthetic group is a carbohydrate or phosphate, covalent bonds would involve the formation of either glycoside linkage between the carbohydrate and amino acids or ester linkage between the phosphate residue and the protein.
== History == The earliest conception of PeptideAtlas began at the Institute for Systems Biology in the research lab of Ruedi Aebersold by Eric Deutsch and Sharon Chen at the Annotated Peptide Database (APD). The concept was further expanded with additional efforts from Parag Mallick and Frank Desiere. The first instance for an ensemble of human experiments was published in 2004 as the Human PeptideAtlas. The concept was further expanded to many other species over the years with major effort by Nichole King, Zhi Sun, Terry Farrah, and Dave Campbell.
Mesenchyme () is a type of loosely organized animal embryonic connective tissue of undifferentiated cells that give rise to many tissues, such as skin, blood, or bone. The interactions between mesenchyme and epithelium help to form nearly every organ in the developing embryo.
The genital self-image and focus for Black women were genital odor and appearance, and the genital self-image and focus for Black men were penis size; racially diverse study sample sizes indicate that, in contrast to women who tend to have a less positive genital self-image, men tend to have a more positive genital self-image.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.